Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 1, Pages 129-137Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.26269
Keywords
hexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safety
Categories
Funding
- GlaxoSmithKline Biologicals SA
Ask authors/readers for more resources
Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11-12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix T hexa (DTPa-HBV-IPV/Hib, Glaxo-SmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been associated with record levels of vaccine coverage, and with sustained disease control in vaccinated cohorts. Hexavalent vaccines will continue to contribute to high vaccine coverage in Italy and across Europe.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available